

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims:

Claim 1-3 (Canceled).

Claim 4 (Currently Amended) A composition comprising five meningococcal antigens: (1) a 'NadA' protein or a variant thereof; (2) a 'NMB1870' protein or a variant thereof; (3) a 'NMB2091' protein or a variant thereof; (4) a 'NMB1030' protein or a variant thereof; and (5) a 'NMB2132' protein or a variant thereof, wherein the composition after administration to a subject is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against a strain from each of two or more of hypervirulent lineages A4, ET-5 and lineage 3 of N.meningitidis serogroup B.

Claim 5 (Canceled).

Claim 6 (Currently Amended) The composition of claim 4 [[5]], wherein the NadA protein comprises SEQ ID 2.

Claim 7 (Canceled).

Claim 8 (Currently Amended) The composition of claim 4 [[7]], wherein the NMB1870 protein comprises SEQ ID 3.

Claim 9 (Canceled).

Claim 10 (Currently Amended) The composition of claim 4 [[9]], wherein the NMB2091 protein comprises SEQ ID 4.

Claim 11 (Canceled).

Claim 12 (Previously Presented) The composition of claim 4 [[11]], wherein NMB1030 protein comprises SEQ ID 5.

Claim 13 (Canceled).

Claim 14 (Currently Amended) The composition of claim 4 [[13]], wherein the NMB2132 protein comprises SEQ ID 6.

Claim 15 (Withdrawn) The composition of claim 4, wherein at least two of the antigens (1) to (5) are expressed as a single polypeptide chain.

Claim 16 (Withdrawn) The composition of claim 4, wherein the two recombinant polypeptides are expressed as a single polypeptide chain and are selected from the group of antigens consisting of: a 'NadA' protein & a 'NMB1870' protein; the 'NadA' protein & a 'NMB2091' protein; the 'NadA' protein & a 'NMB1030' protein; the 'NadA' protein & a 'NMB2132' protein; the 'NMB1870' protein & the 'NMB2091' protein; the 'NMB1870' protein & the 'NMB1030' protein; the 'NMB1870' protein & the 'NMB2132' protein; the 'NMB2091' protein & the 'NMB1030' protein; the 'NMB2091' protein & the 'NMB2132' protein; the 'NMB1030' protein & the 'NMB2132' protein.

Claim 17 (Withdrawn) The composition of claims 15 or 16, wherein the single polypeptide chain comprises a polypeptide of formula $\text{NH}_2\text{-A-X}_1\text{-L-X}_2\text{-B-COOH}$, wherein: X_1 is an amino acid sequence of one of the five antigens selected from the group consisting of the 'NadA' protein, the 'NMB1870' protein; the 'NMB2091' protein; the 'NMB1030' protein; and the 'NMB2132' protein ; X_2 is an amino acid sequence of one of the five antigens selected from the group consisting of the 'NadA' protein, the 'NMB1870' protein; the 'NMB2091' protein; the 'NMB1030' protein; and the 'NMB2132' protein provided that X_1 is not the same as X_2 ; L is an optional linker amino acid sequence; A is an optional N-terminal amino acid sequence; and B is an optional C-terminal amino acid sequence.

Claim 18 (Withdrawn) The composition of claim 17, wherein X_1 is the NMB2091 protein and X_2 is the NMB1870 protein.

Claim 19 (Withdrawn) The composition of claim 17, wherein X_1 is the NMB2132 protein and X_2 is the NMB1030 protein.

Claims 20-21 (Canceled).

Claim 22 (Withdrawn) The composition of claim 4, further comprising saccharide antigens from meningococcus serogroups Y, W135, C and (optionally) A.

Claim 23 (Withdrawn) The composition of claim 4, further comprising a saccharide antigen from *Haemophilus influenzae* type B.

Claim 24 (Withdrawn) The composition of claim 22 or claim 23, wherein the saccharide antigen is conjugated to a carrier selected from: diphtheria toxoid, tetanus toxoid, CRM₁₉₇ or *H.influenzae* protein D.

Claim 25 (Withdrawn) The composition of claim 4, further comprising an antigen from *Streptococcus pneumoniae*.

Claim 26 (Previously Presented) The composition of claim 4 further comprising a pharmaceutically acceptable carrier.

Claim 27 (Canceled).

Claim 28 (Withdrawn) A method for raising an antibody response in a mammal, comprising the step of administering an effective amount of a composition according to any one of claims 4, 15, or 16.

Claims 29-31 (Canceled).